HC Wainwright Expects Increased Earnings for Scholar Rock

Scholar Rock Holding Corporation (NASDAQ:SRRK) – Investment analysts at HC Wainwright raised their FY2026 EPS estimates for Scholar Rock in a report released on Tuesday, November 10th. HC Wainwright analyst A. Maldonado now expects that the company will earn ($3.23) per share for the year, up from their prior estimate of ($3.30). HC Wainwright currently has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for Scholar Rock’s current full-year earnings is ($3.29) per share. HC Wainwright also issued estimates for Scholar Rock’s Q4 2026 earnings at ($0.75) EPS, FY2027 earnings at ($2.66) EPS, FY2028 earnings at ($1.39) EPS, FY2029 earnings at ($0.12) EPS and FY2030 earnings at $1.00 EPS.

Scholar Rock (NASDAQ:SRRK) last posted its earnings results on Tuesday, November 10th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.04. The company had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $0.30 million. During the same period in the previous year, the business posted ($0.90) earnings per share.

Other equities research analysts have also recently issued reports about the company. Truist Financial lifted their target price on Scholar Rock from $76.00 to $77.00 and gave the stock a “buy” rating in a report on Thursday, September 24th. Piper Sandler boosted their target price on Scholar Rock from $60.00 to $75.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 15th. Evercore reissued an “outperform” rating and set a $72.00 price target on shares of Scholar Rock in a research note on Tuesday, September 15th. Wedbush reaffirmed an “outperform” rating and issued a $64.00 price objective on shares of Scholar Rock in a research note on Tuesday, September 15th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Scholar Rock in a report on Monday, September 14th. Four investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $67.67.

Scholar Rock Stock Down 2.9%

SRRK opened at $46.60 on Thursday. The firm has a 50-day simple moving average of $46.64 and a two-hundred day simple moving average of $48.23. Scholar Rock has a 52 week low of $29.35 and a 52 week high of $61.76. The company has a market capitalization of $5.68 billion, a PE ratio of -13.87 and a beta of 0.78. The company has a quick ratio of 7.02, a current ratio of 7.02 and a debt-to-equity ratio of 0.77.

Hedge Funds Weigh In On Scholar Rock

Hedge funds have recently bought and sold shares of the business. GW&K Investment Management LLC purchased a new stake in Scholar Rock in the third quarter worth $17,534,000. Voya Investment Management LLC lifted its position in shares of Scholar Rock by 4.8% during the third quarter. Voya Investment Management LLC now owns 933,359 shares of the company’s stock worth $45,100,000 after purchasing an additional 42,752 shares during the last quarter. Public Sector Pension Investment Board purchased a new stake in shares of Scholar Rock during the third quarter valued at $3,044,000. Russell Investments Group Ltd. boosted its stake in shares of Scholar Rock by 7.5% during the third quarter. Russell Investments Group Ltd. now owns 140,270 shares of the company’s stock valued at $6,778,000 after purchasing an additional 9,756 shares during the period. Finally, Nan Fung Trinity HK Ltd. grew its holdings in shares of Scholar Rock by 164.9% in the third quarter. Nan Fung Trinity HK Ltd. now owns 264,695 shares of the company’s stock worth $12,790,000 after purchasing an additional 164,776 shares during the last quarter. Institutional investors own 91.08% of the company’s stock.

Insiders Place Their Bets

In other news, Director Srinivas Akkaraju acquired 146,970 shares of the firm’s stock in a transaction on Monday, October 26th. The stock was acquired at an average price of $41.59 per share, with a total value of $6,112,482.30. Following the completion of the purchase, the director directly owned 6,380,517 shares in the company, valued at approximately $265,365,702.03. This trade represents a 2.36% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 10.30% of the stock is owned by company insiders.

Scholar Rock News Roundup

Investors following SRRK have been watching these news items:

• Positive Sentiment: HC Wainwright raised its Q4 2026 EPS forecast to a loss of $0.75 from $0.78 and its FY2026 forecast to a loss of $3.23 from $3.30. The firm maintained its Buy rating and $70 price target. Analyst outlook
• Positive Sentiment: Scholar Rock’s Q3 loss of $0.81 per share was narrower than the cited consensus estimate, and the company reported its first product revenue—potentially signaling early commercial progress. Q3 results
• Negative Sentiment: HC Wainwright sharply reduced EPS estimates for FY2027–FY2030: its FY2027 loss estimate increased to $2.66 from $1.95, and it moved FY2029 from projected earnings of $0.47 to a loss of $0.12. Its FY2030 profit estimate was cut to $1.00 from $1.44. These weaker longer-term expectations may weigh on the outlook despite the retained Buy rating.

About Scholar Rock

Scholar Rock is a biopharmaceutical company based in Cambridge, Massachusetts, that develops medicines targeting growth factors and signaling proteins involved in disease. Its research has focused on the transforming growth factor beta (TGF-β) superfamily, which plays roles in processes including muscle development and immune regulation. The company’s lead program has been apitegromab, a selective inhibitor of myostatin developed for spinal muscular atrophy (SMA). Scholar Rock has studied the medicine as a potential treatment alongside existing SMA therapies, with the goal of improving patients’ motor function.